Living with lupus or rheumatoid arthritis (RA) often means relying on medication to manage symptoms and protect long-term health. One of the most commonly prescribed options is Plaquenil (hydroxychloroquine). It has been used safely for decades, but long-term use can affect the eyes if regular monitoring isn't part of your care routine.
The good thing is that Plaquenil-related eye damage is often preventable with routine eye exams and specialized retinal screening. Detecting changes early gives your healthcare team the information needed to make informed treatment decisions before vision is permanently affected.
This article covers how Plaquenil can affect the eyes, who faces higher risk, what symptoms to watch for, and why regular screening matters. We'll also discuss a related concern: corneal toxicity associated with certain cancer immunotherapy treatments.
Plaquenil, also known as hydroxychloroquine, is commonly prescribed to manage autoimmune and inflammatory conditions, including:
By helping regulate immune system activity, Plaquenil can reduce inflammation, joint pain, fatigue, and disease flare-ups. For many patients, it becomes a long-term treatment that meaningfully improves day-to-day life.
Plaquenil is generally considered safe when used as directed, but prolonged use has been associated with an increased risk of hydroxychloroquine retinopathy, a condition that affects the retina.
In some patients, yes. However, not everyone taking Plaquenil will develop eye problems. The primary concern is retinal toxicity, particularly changes to the macula, the central part of the retina responsible for sharp, detailed vision. If retinal toxicity progresses without being detected, it may lead to permanent vision changes in some cases.
Because early retinal changes typically cause no noticeable symptoms, many patients don't realize anything is wrong until damage has already begun. This is why ophthalmologists recommend routine Plaquenil eye exams, even when vision seems perfectly normal.
Hydroxychloroquine retinopathy develops when the medication gradually affects the light-sensitive cells of the retina. Without early detection, patients may experience:
Once retinal changes develop, they aren't always reversible, which is what makes early detection so important.
One of the biggest challenges with hydroxychloroquine retinopathy is that it tends to develop silently. Many patients continue seeing well while subtle retinal changes are already underway. Because noticeable symptoms often appear only after damage has progressed, vision alone isn't a reliable indicator of retinal health.
Routine retinal imaging allows ophthalmologists to identify microscopic changes well before they would ever affect what a patient actually sees.
Not everyone taking Plaquenil carries the same level of risk.
Your risk may be higher if you:
Your ophthalmologist and prescribing physician typically work together to determine an appropriate screening schedule based on these individual risk factors.
A routine vision test alone isn't enough to catch early retinal toxicity. Comprehensive screening relies on specialized diagnostic testing designed to evaluate retinal health before any symptoms appear.
Depending on individual risk factors, an ophthalmologist may recommend:
These tests are painless and non-invasive, and together they play a key role in protecting long-term vision.
Current ophthalmology guidelines generally recommend:
Your eye care provider may recommend a different schedule depending on your dosage, medical history, and overall eye health.
Plaquenil isn't the only medication category associated with eye-related side effects. Some patients receiving cancer immunotherapy may develop symptoms involving the cornea or ocular surface, including:
While these complications differ from Plaquenil-related retinal toxicity, they also call for prompt evaluation and ongoing monitoring. Patients undergoing cancer treatment should notify both their oncologist and their ophthalmologist if new vision changes or eye discomfort develop during therapy as early recognition allows for appropriate treatment and can help reduce the risk of longer-term complications.
Don't wait for symptoms to appear. It's worth scheduling an eye evaluation if you:
Regular eye exams help detect medication-related changes while they're still manageable, rather than after they've progressed.
Plaquenil continues to be an effective medication for many people living with lupus, rheumatoid arthritis, and other autoimmune conditions. While the risk of eye toxicity is relatively low, it should not be overlooked. Routine eye screenings allow ophthalmologists to detect subtle retinal changes before they affect vision, helping patients continue treatment safely whenever possible.
If you're taking Plaquenil or another medication that may affect your eyes, regular comprehensive eye exams are an important part of protecting your long-term vision.
At Remagin, our experienced ophthalmology team uses advanced diagnostic technology to detect medication-related eye changes early and provide personalized care tailored to your needs. Whether you're due for a routine Plaquenil eye exam or have concerns about medication-related vision changes, we're here to help.
Contact us today to schedule a comprehensive eye evaluation and take a proactive step toward protecting your long-term vision.
If retinal toxicity is caught late, vision changes may be permanent. Regular screening significantly improves the chances of identifying issues before serious damage occurs.
Many patients have no symptoms in the early stages. As the condition progresses, some experience blurred vision, blind spots, difficulty reading, or trouble recognizing faces.
Most patients should follow their ophthalmologist's recommended schedule based on current screening guidelines and individual risk factors. Higher-risk patients may need more frequent monitoring.
Yes, in some patients. Certain immunotherapy medications have been associated with dry eye, inflammation, corneal complications, or other ocular side effects. Prompt evaluation by an ophthalmologist is recommended if symptoms develop.
